Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01 2023 - 4:41PM
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a
biopharmaceutical company focused on modality-agnostic targeted
oncology for patients with cancer, today announced that the
compensation committee of the Company's Board of Directors granted
stock option awards to purchase an aggregate of 56,000 shares of
its common stock to three employees outside Cullinan Oncology,
Inc’s 2021 Stock Option and Incentive Plan. The stock options were
granted as an inducement material to the individuals entering into
employment with Cullinan, in accordance with Nasdaq Listing Rule
5635(c)(4).
Three employees received options to purchase an aggregate of
56,000 shares of Cullinan’s common stock on February 1, 2023 and
have an exercise price of $11.58, which is equal to the closing
price of Cullinan’s common stock on February 1, 2023. Each option
has a ten-year term and vests over four years, with 25 percent of
the original number of shares underlying each option vesting on the
one-year anniversary of the vesting commencement date and then in
equal installments for 36 months thereafter, subject to the
employee's continued service with Cullinan through the applicable
vesting dates.
About Cullinan OncologyCullinan Oncology,
Inc. (NASDAQ: CGEM) is a biopharmaceutical company dedicated
to creating new standards of care for patients with cancer. We
innovate without borders to find the most promising clinic-ready
cancer therapies, whether from our own discovery efforts or through
exceptional engagement with our academic and industry partners.
Anchored in a deep understanding of immuno-oncology and
translational cancer medicine, we leverage our scientific
excellence in small molecules and biologics to create
differentiated ideas, identify unique targets, and select the
optimal modality to develop transformative therapeutics across
cancer indications. Powered by our novel research model, we push
conventional boundaries from candidate selection to cancer
therapeutic, applying rigorous early experimentation to fast-track
only the most promising assets to the clinic and ultimately
commercialization. As a result, our diversified pipeline is
strategically built with assets that activate the immune system or
inhibit key oncogenic drivers across a wide range of modalities,
each with the potential to be the best or first in their class.Our
people possess deep scientific expertise, seek innovation openly,
and exercise creativity and urgency to deliver on our promise to
bring new therapeutic solutions to patients with cancer. Learn more
about our Company at www.cullinanoncology.com, and follow us
on LinkedIn and Twitter.
Contacts
Investor Relations
Chad Messer
+1 203.464.8900
cmesser@cullinanoncology.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024